Alcoholics will be given ketamine-assisted therapy as part of a £2.4 million phase three trial to see if it helps them stay off alcohol for longer.
The trial is being led by the University of Exeter but will be delivered across seven NHS sites across the UK. It comes after a phase two trial showed ketamine and therapy treatment was safe and tolerable for heavy drinkers.
The earlier study found that participants who had ketamine combined with therapy stayed completely sober, representing 86% abstinence in the six month follow-up. The National Institute for Health and Care Research (NIHR) is funding the research.
READ MORE: Asda delivery driver 'saved mum' after noticing weird smell outside home
The Ketamine for Reduction of Alcohol Relapse (Kare) trial will now move to the next step of drug development, with the aim of rolling it out into the NHS if it proves effective. Ketamine is a licensed medical drug, widely used as an anaesthetic and in pain relief.
Discover, learn, grow. We are Curiously. Follow us on TikTok, Instagram, Facebook and Twitter.
It is also used as a recreational drug and is classified as a Class B banned substance by the Home Office. The trial will recruit 280 people with alcohol problems who will be randomly split into two groups.
Half the participants will be given ketamine at the dose used in the first clinical trial with psychological therapy. The other half will be given a very low dose of ketamine and a seven-session education package about the harmful effects of alcohol.
Trial lead Professor Celia Morgan, from the University of Exeter, said: “More than two million UK adults have serious alcohol problems, yet only one in five of those get treatment.
“Three out of four people who quit alcohol will be back drinking heavily after a year. Alcohol-related harm is estimated to cost the NHS around £3.5 billion each year, and wider UK society around £40 billion.
“Alcohol problems affect not only the individual but families, friends and communities, and related deaths have increased still further since the pandemic. We urgently need new treatments. If this trial establishes that ketamine and therapy works, we hope we can begin to see it used in NHS settings.”
The new trial will recruit participants across the UK, including Mersey Care NHS Trust.
READ NEXT:
